Literature DB >> 20661233

Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy.

N K El-Mallawany, L Geller, C M Bollard, B Wistinghausen, F Mussai, A S Wayne, B Alobeid, M S Cairo.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20661233      PMCID： PMC3175617          DOI： 10.1038/bmt.2010.176

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  7 in total

1.  False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma.

Authors:  Daniele Focosi; Francesco Caracciolo; Sara Galimberti; Federico Papineschi; Mario Petrini
Journal:  Ann Hematol       Date:  2007-12-18       Impact factor: 3.673

Review 2.  Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru.

Authors:  Carlos Barrionuevo; Virginia M Anderson; Eduardo Zevallos-Giampietri; Mayer Zaharia; Oscar Misad; Francisco Bravo; Héctor Cáceres; Luis Taxa; Marco T Martínez; Antonio Wachtel; Miguel A Piris
Journal:  Appl Immunohistochem Mol Morphol       Date:  2002-03

3.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

4.  Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms.

Authors:  Megan S Lim; Laurence de Leval; Leticia Quintanilla-Martinez
Journal:  J Hematop       Date:  2009-06-27       Impact factor: 0.196

5.  Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.

Authors:  Emiko Sato; Shouichi Ohga; Hiroshi Kuroda; Fumiaki Yoshiba; Miki Nishimura; Masayuki Nagasawa; Masami Inoue; Keisei Kawa
Journal:  Am J Hematol       Date:  2008-09       Impact factor: 10.047

6.  Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

Authors:  Paolo Corradini; Anna Dodero; Francesco Zallio; Daniele Caracciolo; Marco Casini; Marco Bregni; Franco Narni; Francesca Patriarca; Mario Boccadoro; Fabio Benedetti; A Rambaldi; Alessandro M Gianni; Corrado Tarella
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

7.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Authors:  Catherine M Bollard; Stephen Gottschalk; Ann M Leen; Heidi Weiss; Karin C Straathof; George Carrum; Mariam Khalil; Meng-fen Wu; M Helen Huls; Chung-Che Chang; M Victoria Gresik; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113
  7 in total
  6 in total

Review 1.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

2.  Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.

Authors:  M S Zinter; A Melton; A J Sabnis; C C Dvorak; B M Elicker; H M Nawaytou; R J Kameny; J R Fineman
Journal:  Leuk Lymphoma       Date:  2017-09-28

Review 3.  Systemic lymphoma arising from hydroa vacciniforme-like lymphoma: report of two cases with review of literature.

Authors:  Yu-Qiong Yang; Lei Fan; Li Wang; Ji Xu; Run Zhang; Zheng Ge; Jian-Yong Li; Wei Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

4.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

5.  Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection.

Authors:  Elżbieta Grześk; Sylwia Kołtan; Anna Dąbrowska; Anna Urbańczyk; Jadwiga Małdyk; Bogdan Małkowski; Tomasz Bogiel; Robert Dębski; Krzysztof Czyżewski; Mariusz Wysocki; Jan Styczyński
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

6.  Hydroa Vacciniforme-Like Lymphoma with Systemic Symptoms: Two Case Reports.

Authors:  Litao Wang; Yuwen Su; Jianzhong Zhang; Haiquan Wen; Guiying Zhang
Journal:  Indian J Dermatol       Date:  2019 Nov-Dec       Impact factor: 1.494
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.